Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Bejar

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Current Hematologic Malignancy Reports|July 2, 2015
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Rafael Bejar
Best Practice & Research. Clinical Haematology|November 24, 2018
What biologic factors predict for transformation to AML?Rafael Bejar
Best Practice & Research. Clinical Haematology|December 14, 2022
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigmsRafael Bejar
Best Practice & Research. Clinical Haematology|December 14, 2022
How can we incorporate molecular data into the IPSS?Rafael Bejar
Hematology. American Society of Hematology. Education Program|December 10, 2013
Prognostic models in myelodysplastic syndromesRafael Bejar
Best Practice & Research. Clinical Haematology|December 6, 2021
How do molecular aberrations guide therapy in MDS?Rafael Bejar
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Advances in Personalized Therapeutic Approaches in Myelodysplastic SyndromesRafael Bejar
Current Opinion in Hematology|November 23, 2016
Implications of molecular genetic diversity in myelodysplastic syndromesRafael Bejar
Blood|April 27, 2023
Newly revised 2023 MDS response criteriaRafael Bejar
Advances in Experimental Medicine and Biology|June 4, 2016
Splicing Factor Mutations in CancerRafael Bejar
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Current Hematologic Malignancy Reports|July 2, 2015
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Rafael Bejar
Best Practice & Research. Clinical Haematology|November 24, 2018
What biologic factors predict for transformation to AML?Rafael Bejar
Best Practice & Research. Clinical Haematology|December 14, 2022
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigmsRafael Bejar
Best Practice & Research. Clinical Haematology|December 14, 2022
How can we incorporate molecular data into the IPSS?Rafael Bejar
Hematology. American Society of Hematology. Education Program|December 10, 2013
Prognostic models in myelodysplastic syndromesRafael Bejar
Best Practice & Research. Clinical Haematology|December 6, 2021
How do molecular aberrations guide therapy in MDS?Rafael Bejar
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
Advances in Personalized Therapeutic Approaches in Myelodysplastic SyndromesRafael Bejar
Current Opinion in Hematology|November 23, 2016
Implications of molecular genetic diversity in myelodysplastic syndromesRafael Bejar
Blood|April 27, 2023
Newly revised 2023 MDS response criteriaRafael Bejar
Advances in Experimental Medicine and Biology|June 4, 2016
Splicing Factor Mutations in CancerRafael Bejar
Pageof 11